Insulet Corp. logo
PODDInsulet Corp.

Is the P/E ratio high or low?

The P/E ratio of 34.62 is 99% below its 5-year average of 3790.02, near the low end of its 5-year range (32.32–64750.98).

As of Thursday, June 25, 2026. 52.25% below its 12-month average of 72.50.

PE Ratio (34.62) = Close Price ($148.88) / Diluted TTM EPS ($4.30)

PODD PE Ratio

PODD PE Ratio Chart

34.62
-38.09% 1Y
PODD PE Ratio

PODD Average PE Ratio Chart

PODD PE Ratio

PODD Current vs Average PE Ratio Chart

PODD PE Ratio Metrics

PE RATIO

34.62

PE RATIO AVG TTM

72.50

PE RATIO AVG 3Y

69.23

PE RATIO AVG 5Y

254.13

PE RATIO AVG 10Y

N/A

PE RATIO AVG 15Y

N/A

PE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-52.25%

CURRENT VS 3Y AVG

-49.99%

CURRENT VS 5Y AVG

-86.38%

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

PODD Competitors' PE Ratio

NAMEMARKET CAPPE RATIOTTM3Y5Y
Insulet Corp. (PODD)$10.31B34.6272.5069.23254.13
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37BN/A33.4814.6325.08
Baxter International Inc. (BAX)vs ›$10.87BN/A44.5334.4137.43
Charles River Laboratories International, Inc. (CRL)vs ›$9.73BN/A225.6691.3972.20
Henry Schein, Inc. (HSIC)vs ›$9.55B25.0222.8823.6021.61
Revvity, Inc. (RVTY)vs ›$11.78B50.3044.1041.2233.85
Align Technology, Inc. (ALGN)vs ›$12.24B28.6729.1642.2547.23
Bio-Rad Laboratories, Inc. (BIO)vs ›$7.57B46.1425.0025.0013.01
Oscar Health, Inc. (OSCR)vs ›$7.56BN/A60.9260.9260.92
Solventum Corporation (SOLV)vs ›$13.09B9.2518.0916.9616.96

P/E vs. its own history

At 34.6, P/E is at an extreme level (the multiple carries little signal here), sitting higher than 1% of its 7-year history.

7-year low

32.3

median

508.8

7-year high

64751.0

cheaperricher

P/E Comparison

Trailing P/E

34.6

Forward P/E

18.4

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$148.88

÷

Forward EPS (Est.)

$8.11

=

Forward P/E

18.35

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PE Ratio FAQ

What is the P/E ratio for Insulet Corp. (PODD)?
The P/E ratio for PODD stock is 34.62.
Is Insulet Corp.'s P/E ratio high or low?
The P/E ratio of 34.62 is 99% below its 5-year average of 3790.02, near the low end of its 5-year range (32.32–64750.98).
What is the TTM average P/E ratio for Insulet Corp. (PODD)?
The TTM average P/E ratio for PODD stock is 72.50.
What is the 3Y average P/E ratio for Insulet Corp. (PODD)?
The 3Y average P/E ratio for PODD stock is 69.23.
What is the 5Y average P/E ratio for Insulet Corp. (PODD)?
The 5Y average P/E ratio for PODD stock is 254.13.

PODD PE Ratio History

DATEPE RATIO
2026-06-2434.62
2026-06-2333.47
2026-06-2232.32
2026-06-1833.90
2026-06-1733.38
2026-06-1634.35
2026-06-1534.45
2026-06-1234.81
2026-06-1134.70
2026-06-1035.05
2026-06-0937.12
2026-06-0835.23
2026-06-0535.63
2026-06-0434.05
2026-06-0333.33
2026-06-0233.12
2026-06-0134.45
2026-05-2933.71
2026-05-2833.17
2026-05-2733.96
2026-05-2635.77
2026-05-2236.02
2026-05-2136.49
2026-05-2036.42
2026-05-1935.96
2026-05-1835.46
2026-05-1534.29
2026-05-1434.58
2026-05-1334.61
2026-05-1236.83
2026-05-1135.85
2026-05-0835.85
2026-05-0737.30
2026-05-0635.18
2026-05-0547.87
2026-05-0448.97
2026-05-0150.01
2026-04-3049.18
2026-04-2945.72
2026-04-2852.25
2026-04-2753.80
2026-04-2454.16
2026-04-2354.92
2026-04-2255.32
2026-04-2154.95
2026-04-2057.39
2026-04-1758.21
2026-04-1657.56
2026-04-1557.86
2026-04-1457.57
2026-04-1356.52
2026-04-1056.27
2026-04-0956.98
2026-04-0858.15
2026-04-0757.85
2026-04-0658.14
2026-04-0258.37
2026-04-0159.15
2026-03-3159.95
2026-03-3059.43
2026-03-2759.49
2026-03-2662.32
2026-03-2561.71
2026-03-2464.43
2026-03-2364.88
2026-03-2064.89
2026-03-1965.32
2026-03-1865.79
2026-03-1765.85
2026-03-1664.19
2026-03-1362.81
2026-03-1267.45
2026-03-1168.23
2026-03-1068.07
2026-03-0968.68
2026-03-0667.72
2026-03-0568.84
2026-03-0469.40
2026-03-0369.10
2026-03-0270.13
2026-02-2770.46
2026-02-2671.86
2026-02-2570.89
2026-02-2470.07
2026-02-2371.25
2026-02-2069.11
2026-02-1971.17
2026-02-1873.73
2026-02-1771.40
2026-02-1370.36
2026-02-1269.80
2026-02-1172.71
2026-02-1073.16
2026-02-0971.18
2026-02-0670.12
2026-02-0570.48
2026-02-0472.82
2026-02-0372.82
2026-02-0274.38
2026-01-3074.15
2026-01-2973.94
2026-01-2874.84
2026-01-2776.79
2026-01-2678.64
2026-01-2378.72
2026-01-2281.16
2026-01-2182.60
2026-01-2082.39
2026-01-1683.39
2026-01-1583.04
2026-01-1482.00
2026-01-1380.63
2026-01-1280.74
2026-01-0983.78
2026-01-0884.90
2026-01-0786.72
2026-01-0685.32
2026-01-0582.18
2026-01-0282.01
2025-12-3182.39
2025-12-3083.20
2025-12-2983.29
2025-12-2683.66
2025-12-2483.72
2025-12-2382.75
2025-12-2284.51
2025-12-1983.95
2025-12-1884.89
2025-12-1783.93
2025-12-1683.69
2025-12-1584.50
2025-12-1285.71
2025-12-1185.27
2025-12-1085.56
2025-12-0985.28
2025-12-0885.85
2025-12-0588.26
2025-12-0491.57
2025-12-0389.15
2025-12-0289.57
2025-12-0190.10
2025-11-2894.84
2025-11-2694.72
2025-11-2595.32
2025-11-2497.83
2025-11-2195.99
2025-11-2090.69
2025-11-19100.39
2025-11-1896.66
2025-11-1795.08
2025-11-1496.43
2025-11-1396.43
2025-11-1297.63
2025-11-1194.57
2025-11-1092.86
2025-11-0792.70
2025-11-0693.74
2025-11-0595.57
2025-11-0497.35
2025-11-0396.89
2025-10-3195.14
2025-10-3094.82
2025-10-2996.10
2025-10-2898.58
2025-10-2799.03
2025-10-2497.54
2025-10-2398.32
2025-10-22100.07
2025-10-2199.99
2025-10-2099.35
2025-10-1796.84
2025-10-1696.14
2025-10-1594.97
2025-10-1496.75
2025-10-1395.61
2025-10-1095.60
2025-10-0997.38
2025-10-0895.89
2025-10-0795.27
2025-10-0694.74
2025-10-0393.96
2025-10-0294.90
2025-10-0193.00
2025-09-3093.84
2025-09-2994.41
2025-09-2696.66
2025-09-2598.35
2025-09-2499.38
2025-09-2399.64
2025-09-22101.86
2025-09-19100.56
2025-09-18101.37
2025-09-1797.94
2025-09-16100.95
2025-09-15103.43
2025-09-12103.88
2025-09-11102.72
2025-09-10102.62
2025-09-09107.24
2025-09-08106.25
2025-09-05105.91
2025-09-04105.31
2025-09-03104.42
2025-09-02104.84
2025-08-29103.31
2025-08-28102.61
2025-08-27101.63
2025-08-26100.86
2025-08-25100.00
2025-08-22100.54
2025-08-2199.65
2025-08-20101.22
2025-08-1999.54
2025-08-1898.20
2025-08-1597.65
2025-08-1495.98
2025-08-1393.82
2025-08-1294.11
2025-08-1192.66
2025-08-0893.34
2025-08-0792.26
2025-08-0649.87
2025-08-0550.54
2025-08-0451.76
2025-08-0151.24
2025-07-3151.87
2025-07-3053.65
2025-07-2952.43
2025-07-2852.57
2025-07-2552.20
2025-07-2451.54
2025-07-2351.56
2025-07-2251.36
2025-07-2150.53
2025-07-1851.12
2025-07-1750.98
2025-07-1651.85
2025-07-1552.16
2025-07-1452.52
2025-07-1152.04
2025-07-1053.49
2025-07-0953.50
2025-07-0853.33
2025-07-0754.08
2025-07-0354.15
2025-07-0254.25
2025-07-0153.96
2025-06-3056.51
2025-06-2756.31
2025-06-2655.72
2025-06-2555.08
2025-06-2455.92
2025-06-2355.34
2025-06-2054.52
2025-06-1854.28
2025-06-1754.75
2025-06-1655.14
2025-06-1354.79
2025-06-1254.61
2025-06-1154.36

Showing the most recent 260 of 1,704 data points. The chart above shows the full history.

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy